Warning: Creating default object from empty value in /home/altaywgm/public_html/wp-content/plugins/gaviasframework/redux/redux-framework/inc/class.redux_filesystem.php on line 29
New Indication: Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA) - Altai Oncology

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Kütüphanede Ara Ara

New Indication: Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA)

New Indication: Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA)
Study:
  • Open-label, multicentre, phase 3 study
  • Untreated CLL or SLL
  • Patients without del (17) (p13·1)  zanubrutinib (group A; n=241) or bendamustine–rituximab (group B; n=238) and patients with del(17) (p13·1) zanubrutinib
Efficacy:
  • mPFS was significantly improved in group A versus group B (HR 0·42 [95% CI 0·28 – 0·63]; p<0·0001)
  • 24 months PFS: 85·5% in group A and 69·5% in group B
  • ORR: 94·6% in group A and 85·3% in group B
  • CR rate: 7% in group A and 15% in group B
Safety:
  • Grade 1-2 any AEs: 41% vs 16% (group A vs group B)
  • Grade ≥3 AEs neutropenia 11% vs 51%, infections 16% vs 19%
  • Grade 1-2 all bleeding AE: 41% vs 9%

Lancet Oncol. 2022 Aug;23(8):1031-1043.

Tam CS, Brown JR, Kahl BS, et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial

https://doi.org/10.1016/s1470-2045(22)00293-5

Reviewed by Hasan Çağrı Yıldırım, MD on Aug 16, 2022

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More